Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
Akl Fahed, Shinwan Kany/LinkedIn
Aug 31, 2026, 14:24

Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?

Akl Fahed, Interventional Cardiologist and Physician-Scientist at Massachusetts General Hosptal, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC, adding:

“Excited to share our new study presented today at European Society of Cardiology ESC 2026 in Munich and simultaneously published in JACC Journals

Do lifelong differences in LDL cholesterol influence the risk of venous thromboembolism (VTE)?

Prior clinical studies have suggested that lipid-lowering therapies may modestly reduce VTE. But whether this benefit is actually mediated by lowering LDL-C, or by other effects of these therapies, has remained unclear.

We used human genetics as a natural experiment, analyzing sequencing data from more than 700,000 participants in UK Biobank and All of Us.

We examined rare functional variants in LDLR, APOB, and PCSK9 that produce remarkably large, lifelong differences in LDL-C, up to approximately 50 percent.

Despite these profound differences in lifelong LDL-C exposure, we found no consistent association with VTE risk across genes, cohorts, or sensitivity analyses.

Additional common-variant and Mendelian randomization analyses suggest that previously reported associations between LDL-C and VTE may partly reflect obesity and broader metabolic pathways, rather than LDL-C itself.

Take-home: LDL-C itself is unlikely to be a major causal determinant of VTE.

If lipid-lowering therapies reduce VTE, the benefit may involve LDL-independent metabolic, inflammatory, endothelial, or antithrombotic mechanisms, an important distinction for understanding how these therapies work and for identifying future targets for VTE prevention.”

Title: Genetically Mediated Differences in LDL Cholesterol and Risk of Venous Thromboembolism

Authors: Yang Sui, Shinwan Kany, Shaan Khurshid, Kelvin Supriami, Joel T. Rämö, Sean J. Jurgens, Nobuyuki Enzan, Seung Hoan, Zhi Yu, Linke Li, Buu Truong, Xingyu Chen, Min Seo Kim, Injeong Shim, Raphael Twerenbold, James P. Piruccello, Pradeep Natarajan, Patrick T. Ellinor, Akl C. Fahed

Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?

Stay updated on all scientific advances with Hemostasis Today.

Akl C Fahed Akl Fahed All of Us APOB Buu Truong Cardiology Cardiovascular Disease cardiovascular risk Clinical Research ESC 2026 evidence-based medicine Genetically Mediated LDL Cholesterol Hemostasis Hemostasis News Hemostasis Today Human Genetics Injeong Shim JACC James P. Piruccello Joel T. Rämö Kelvin Supriami LDL Cholesterol LDL-C LDLR Linke Li Lipid Metabolism medical education Medical Research Mendelian randomization Min Seo Kim Nobuyuki Enzan Patrick T. Ellinor PCSK9 Pradeep Natarajan Raphael Twerenbold Sean J. Jurgens Seung Hoan Shaan Khurshid Shinwan Kany thrombosis UK Biobank venous thromboembolism VTE Xingyu Chen Yang Sui Zhi Yu
NewsFeed